clinical trial · NCT05649748
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial HypertensionTreprostinil PalmitilPlacebo
brief summary
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
started
Mar 7, 2023
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Apr 14, 2026
official title
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol